Daniel Brigham
Impact in
- Hematology top 2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
-
- Acute Myeloid Leukemia Research 4
- Chronic Myeloid Leukemia Treatments 3
- Genetics 4
- Chronic Lymphocytic Leukemia Research 4
- Co-authors
- Andrea Marra (3 shared papers)Michael F. Gardner (3 shared papers)Barbara Belli (6 shared papers)Robert C. Armstrong (4 shared papers)Patrick P. Zarrinkar (3 shared papers)Keith W. Pratz (1 shared paper)Mazen W. Karaman (1 shared paper)Gabriel Pallares (1 shared paper)
- Journals
- Infection and Immunity (2 papers)Blood (2 papers)Cancer Research (2 papers)European Journal of Philosophy (1 paper)Microbiology (1 paper)
- Partner nations
- United StatesUnited Kingdom
In The Last Decade
Daniel Brigham
9 papers receiving 742 citations
Daniel Brigham's Hit Papers
Peers
Comparison fields: 5 of 69
- Hematology 381
- Genetics 159
- Microbiology 82
- Molecular Medicine 36
- Epidemiology 146
Countries citing papers authored by Daniel Brigham
This map shows the geographic impact of Daniel Brigham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Brigham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Brigham more than expected).
Fields of papers citing papers by Daniel Brigham
This network shows the impact of papers produced by Daniel Brigham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Brigham. The network helps show where Daniel Brigham may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Brigham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML) Hit paper breakdown → | 2009 | 491 |
| 2 | 2002 | 101 | |
| 3 | 2002 | 82 | |
| 4 | 2001 | 50 | |
| 5 | 2015 | 17 | |
| 6 | 2012 | 10 | |
| 7 | 2009 | 3 | |
| 8 | 2017 | 2 | |
| 9 | 2010 | 1 | |
| 10 | 2016 | 1 | |
| 11 | Abstract #2335: AC220, a uniquely potent and selective FLT3 inhibitor, provides sustained protection in a FLT3 ITD driven model of acute myeloid leukemia | 2009 | 0 |
About Daniel Brigham
Daniel Brigham is a scholar working on Hematology, Genetics, Molecular Biology, Epidemiology and Microbiology, having authored 11 papers that have together received 758 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Bacterial Infections and Vaccines (3 papers), Pneumonia and Respiratory Infections (3 papers), Epistemology, Ethics, and Metaphysics (2 papers), Angiogenesis and VEGF in Cancer (1 paper) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Hematology (381 citations), Genetics (159 citations), Microbiology (82 citations), Molecular Medicine (36 citations) and Epidemiology (146 citations). Daniel Brigham has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Andrea Marra, Michael F. Gardner, Barbara Belli, Robert C. Armstrong, Patrick P. Zarrinkar, Keith W. Pratz, Mazen W. Karaman, Gabriel Pallares, Mark J. Levis and Hitesh Patel. Their work appears in journals such as Infection and Immunity, Blood, Cancer Research, European Journal of Philosophy and Microbiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.